National and Kapodistrian University of Athens
Φαρμακομόρια πολλαπλής στόχευσης με πιθανή δράση σε νευροεκφυλιστικές και άλλες πολυπαραγοντικές νόσους: σχεδιασμός, σύνθεση και φαρμακολογική αξιολόγηση
Abstract
dc:descriptionNeurodegeneration is a complex pathophysiological condition, that has been correlated to conditions, such as oxidative stress, inflammation and neuroinflammation, dysregulation of cholesterol homeostasis (inside and outside of the brain), accumulation of metal ions in neurons etc. Furthermore, there is an established relationship between metabolic syndrome and neurodegeneration, which renders metabolic syndrome a new, promising target against neurodegeneration. The aim of this dissertation is the design, synthesis and pharmacological evaluation of new multitarget compounds, as agents with potential antidegenerative properties, that will combine structural moieties with antioxidant, anti-inflammatory and antihyperlipidemic activity, as well as potential inhibitory activity against acetylcholinesterase. In this context, thiomorpholine and benzothiomorpholine core structures, based on previously developed inhibitors of squalene synthase, were combined with moieties that bear one or more other activities, such as antioxidant and/or anti-inflammatory. Such moieties are (poly)phenolic acids, chromane analogues and known NSAIDs. In total, 3 series of novel compounds were designed and synthesized via synthetic routes of 2-7 steps, in relatively good to excellent yields (50-99%). The final 39 compounds were characterized by 1H-NMR and 13C-NMR spectroscopy and were evaluated both in vitro and in vivo, for their antioxidant, anti-inflammatory and antihyperlipidemic properties, as well as their ability to chelate metal ions and inhibit acetylcholinesterase. Moreover, docking studies were performed, in an attempt to correlate the experimental and theoretical data, regarding the activity of the compounds on lipoxygenase and/or acetylcholinesterase. Further, cell cultures studies were conducted for selected derivatives of the first series, involving the evaluation of cytotoxicity/survival rates in their presence, as well as preliminary studies on the effect of two compounds on autophagy-related proteins. Finally, the probability for the crossing of the new compounds through the blood brain barrier was calculated. The first series of molecules (derivatives of chromane analogue Trolox, hydroxybenzoic acid derivative and its alcohol, esterified with known non-steroidal anti-inflammatory agents and nicotinic acid) had remarkable in vitro antioxidant properties, with the most active compounds bearing IC50 values of 0,8-7μΜ for lipid peroxidation and increasing the total antioxidant capacity of plasma by up to 761%. The best compounds inhibited the enzyme acetylcholinesterase by up to 90% at 150μM, while most of the compounds showed satisfactory anti-inflammatory properties, in vitro and in vivo. The second series of compounds (amides of thiomorpholine with phenolic acids and their analogues, BHT and derivative, Trolox, cinnamic or nicotinic acid and ibuprofen) showed significant results in vitro and in vivo, increasing plasma total antioxidant capacity by up to 800%. The anti-dyslipidemic properties were impressive, since all tested compounds contributed significantly to all lipid parameters, reducing total cholesterol, triglycerides and LDL by up to 70% and increasing HDL by up to 95%. Moreover, almost all compounds of this series increased the antiatheromatic index by 43-682%, which confirms the remarkable anti-dyslipidemic properties of all molecules. The anti-inflammatory activity of the new compounds was also significant, in vitro and in vivo. The third series of molecules (amides of benzothiomorpholine with phenolic acids and their derivatives, BHT and derivative, ibuprofen and hydroxy-benzothiomorpholine analogues with a naproxen-resembling moiety) had satisfactory in vitro antioxidant properties. The in vivo evaluation of the anti-dyslipidemic activity had impressive results, with all derivatives reducing lipid parameters of total cholesterol, triglycerides and LDL by almost 70% and increasing HDL levels by up to 130%. In total, the antiatheromatic index was elevated by 230-600%, underlining the remarkable anti-dyslipidemic activity of this series. The anti-inflammatory activity of the new derivatives was shown both in vitro and in vivo. In conclusion, the majority of the derivatives of the present dissertation confirmed both in vitro and in vivo at least two of three activities, for which they were initially designed (antioxidant, anti-inflammatory and antihyperlipidemic). Moreover, the interaction of the new compounds with the enzyme acetylcholinesterase showed promising results. At the same time, theoretical calculations of physicochemical properties of all new compounds, as well as their probability of crossing through blood brain barrier, show potential for CNS activity for 90% of the new compounds. This renders the best acting compounds of this dissertation as promising lead compounds for future research approaches towards the development of multitarget compounds against neurodegeneration and/or other multifactorial diseases.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tzara, Ariadni
- Τζάρα, Αριάδνη
Subjects
dc:subject × 18- Αντιοξειδωτική δράση
- Αντιφλεγμονώδης δράση
- Αντιυπερλιπιδαιμική δράση
- Πολυλειτουργικά μόρια
- Θειομορφολίνη
- Βενζοθειομορφολίνη
- Antioxidant activity
- Antiinflammatory activity
- Antihyperlipidemic activity
- Multifunctional
- Thiomorpholine
- Benzothiomorpholine
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, γενικά
- Health Sciences
- Medical and Health Sciences
- Health sciences, general
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60302